Update on the COVID-19 pandemic

Information regarding COVID-19 is in constant change, as is the situation regarding vaccination and prioritization for immune-compromised individuals.

If you have any COVID-19-related questions, we’ve created a specific COVID section on our website that can be accessed by clicking here or by selecting the “News & Events” tab from our homepage. In this section, you’ll find the latest news and information about the pandemic in Canada from trustworthy and reliable sources.

Any specific questions that you may have regarding the COVID-19 vaccination, delays between vaccine dosing, and prioritization within your province are best answered by your healthcare team. They’re the ones who know you and your particular situation and are therefore in a position to best address your unique concerns.

Created by, and entirely focused on, Canadians impacted by myeloma, Myeloma Canada is the only national charitable organization committed to providing you with the most up-to-date and reliable information on myeloma. Some of the ways we do this is through our monthly e-newsletter, “Myeloma Matters”, as well as through our social media platforms.

Please don’t hesitate to contact us at contact@myeloma.ca or toll-free at 1-888-798-5771 with any questions regarding our programs and services.

Close

Make a donation

Myeloma Canada Scientific Roundtable

First Roundtable in 2009

Each year, the annual Myeloma Canada Scientific Roundtable brings together over 80 stakeholders, including Canada's top myeloma experts from coast to coast, scientists from the USA and Europe, our industry research partners and patients. The meeting is an incubator for clinical trial ideas and supports our goal of developing high-impact made-in- Canada clinical trials for patients across the country. The MCRN's clinical trial portfolio continues to grow and with the recent launch of the MCRN Canadian Multiple Myeloma Database, we will now be able to gather patient outcome data from across the country to better identify the optimal treatment approaches.

2017 Scientific Roundtable

On September 15 and 16, Myeloma Canada hosted the 8th annual Myeloma Canada Scientific Roundtable in Montreal. Co-chaired by Dr. Jonathan Keats from Phoenix, Arizona and Dr. Victor Zepeda from Calgary, the meeting brought together over 90 stakeholders, including Canada's top myeloma experts from coast to coast, scientists from the USA and Europe, our industry research partners and patient contributors. This year's international guest speakers included Dr. Ashutosh Wechalekar from London, UK, Dr. Peter Voorhees from Chapel Hill, NC, Dr. Dirk Hose from Heidelberg, DE, Dr. Shaji Kumar from Rochester, MN, Dr. Jesús Berdeja from Nashville, TN, and Dr. Rafael Fonseca from Scottsdale, AZ.

A wide range of current topics in myeloma research were discussed, including monoclonal gammopathy of undetermined significance (MGUS) and smouldering myeloma, amyloid, minimal residual disease, CAR T-cell therapy and more.
 
The meeting is an incubator for clinical trial ideas and supports our goal of developing high-impact made-in-Canada clinical trials for patients across the country. The conference was a huge success, with each year proving to be better than the last. The highly valuable presentations and topics sparked important discussions, the sharing of ideas and a forward-thinking thought processes. All in all, the event invoked a positive sense of motivation and collaboration amongst all who attended.